Post Void Dribbling Clinical Trial Drug Information

Vesicare® (solifenacin succinate) is a muscarinic receptor antagonist. Chemically, solifenacin succinate is butanedioic acid, compounded with (1S)-(3R)-1-azabicyclo [2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-iso- quinoline carboxylate (1:1) having an empirical formula of C23H26N2O2 C4H6O4, and a molecular weight of 480.55.


The structural formula of solifenacin succinate is:

Structural formula of Vesicare® (solifenacin succinate)

Solifenacin succinate is a white to pale-yellowish-white crystal or crystalline powder. It is stable at room temperature. It is freely soluble at room temperature in water, glacial acetic acid, dimethyl sulfoxide and methanol. Each Vesicare tablet contains 5 mg of solifenacin succinate and is formulated for oral administration.


In addition to the active ingredient solifenacin succinate, each Vesicare tablet also contains the following inert ingredients: lactose monohydrate, corn starch, hypromellose 2910, magnesium stearate, talc, polyethylene glycol 8000 and titanium dioxide with yellow ferric oxide (5 mg Vesicare tablet) or red ferric oxide (10 mg Vesicare tablet). Vesicare (solifenacin) 5mg by mouth daily will be used for this study.


  • This drug is known to be safe for use. The drug used in this study has been approved for use by the FDA for the treatment of urgency, nocturia, urinary frequency and urge incontinence. It has been clinically available in the United States since 2005.